{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T13:43:28Z","timestamp":1791726208193,"version":"4.3.4"},"reference-count":43,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2020,5,14]],"date-time":"2020-05-14T00:00:00Z","timestamp":1589414400000},"content-version":"unspecified","delay-in-days":13,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2020,4,1]]},"published-print":{"date-parts":[[2020,5]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>PD1\/PDL1-directed therapies have been unsuccessful for multiple myeloma (MM), an incurable cancer of plasma cells in the bone marrow (BM). Therefore, other immune checkpoints such as extracellular adenosine and its immunosuppressive receptor should be considered. CD39 and CD73 convert extracellular ATP to adenosine, which inhibits T-cell effector functions via the adenosine receptor A2A (A2AR). We set out to investigate whether blocking the adenosine pathway could be a therapy for MM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Expression of CD39 and CD73 on BM cells from patients and T-cell proliferation were determined by flow cytometry and adenosine production by Liquid chromatograpy-mass spectrometry (HPCL\/MS). ENTPD1 (CD39) mRNA expression was determined on myeloma cells from patients enrolled in the publicly available CoMMpass study. Transplantable 5T33MM myeloma cells were used to determine the effect of inhibiting CD39, CD73 and A2AR in mice in vivo.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Elevated level of adenosine was found in BM plasma of MM patients. Myeloma cells from patients expressed CD39, and high gene expression indicated reduced survival. CD73 was found on leukocytes and stromal cells in the BM. A CD39 inhibitor, POM-1, and an anti-CD73 antibody inhibited adenosine production and reduced T-cell suppression in vitro in coculture of myeloma and stromal cells. Blocking the adenosine pathway in vivo with a combination of Sodium polyoxotungstate (POM-1), anti-CD73, and the A2AR antagonist AZD4635 activated immune cells, increased interferon gamma production, and reduced the tumor load in a murine model of MM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our data suggest that the adenosine pathway can be successfully targeted in MM and blocking this pathway could be an alternative to PD1\/PDL1 inhibition for MM and other hematological cancers. Inhibitors of the adenosine pathway are available. Some are in clinical trials and they could thus reach MM patients fairly rapidly.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2020-000610","type":"journal-article","created":{"date-parts":[[2020,5,14]],"date-time":"2020-05-14T13:21:28Z","timestamp":1589462488000},"page":"e000610","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":128,"title":["Conversion of ATP to adenosine by CD39 and CD73 in multiple myeloma can be successfully targeted together with adenosine receptor A2A blockade"],"prefix":"10.1136","volume":"8","clinical-trial-number":[{"clinical-trial-number":"nct02503774","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02740985","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03454451","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03454451","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02503774","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Rui","family":"Yang","sequence":"first","affiliation":[{"name":"Center for Myeloma Research, Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU), Trondheim, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samah","family":"Elsaadi","sequence":"additional","affiliation":[{"name":"Center for Myeloma Research, Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU), Trondheim, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristine","family":"Misund","sequence":"additional","affiliation":[{"name":"Center for Myeloma Research, Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU), Trondheim, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pegah","family":"Abdollahi","sequence":"additional","affiliation":[{"name":"Center for Myeloma Research, Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU), Trondheim, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esten Nymoen","family":"Vandsemb","sequence":"additional","affiliation":[{"name":"Center for Myeloma Research, Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU), Trondheim, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siv Helen","family":"Moen","sequence":"additional","affiliation":[{"name":"Center for Myeloma Research, Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU), Trondheim, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Kusnierczyk","sequence":"additional","affiliation":[{"name":"PROMEC, Department for Clinical and Molecular Medicine, NTNU, Trondheim, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geir","family":"Slupphaug","sequence":"additional","affiliation":[{"name":"PROMEC, Department for Clinical and Molecular Medicine, NTNU, Trondheim, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Therese","family":"Standal","sequence":"additional","affiliation":[{"name":"Center for Myeloma Research, Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU), Trondheim, Norway"},{"name":"CEMIR (Centre of Molecular Inflammation Research), Department of Clinical and Molecular Medicine, NTNU, Trondheim, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Waage","sequence":"additional","affiliation":[{"name":"Center for Myeloma Research, Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU), Trondheim, Norway"},{"name":"Department of Hematology, St. Olavs Hospital, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias S","family":"Sl\u00f8rdahl","sequence":"additional","affiliation":[{"name":"Center for Myeloma Research, Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU), Trondheim, Norway"},{"name":"Department of Hematology, St. Olavs Hospital, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torstein Baade","family":"R\u00f8","sequence":"additional","affiliation":[{"name":"Center for Myeloma Research, Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU), Trondheim, Norway"},{"name":"Children\u2019s Clinic, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Even","family":"Rustad","sequence":"additional","affiliation":[{"name":"Center for Myeloma Research, Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU), Trondheim, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Sundan","sequence":"additional","affiliation":[{"name":"Center for Myeloma Research, Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU), Trondheim, Norway"},{"name":"CEMIR (Centre of Molecular Inflammation Research), Department of Clinical and Molecular Medicine, NTNU, Trondheim, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl","family":"Hay","sequence":"additional","affiliation":[{"name":"Oncology R&D, AstraZeneca Medimmune, Gaithersburg, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1059-0940","authenticated-orcid":false,"given":"Zachary","family":"Cooper","sequence":"additional","affiliation":[{"name":"Oncology R&D, AstraZeneca Medimmune, Gaithersburg, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alwin G","family":"Schuller","sequence":"additional","affiliation":[{"name":"Bioscience, AstraZeneca R&D Boston, Waltham, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Woessner","sequence":"additional","affiliation":[{"name":"Bioscience, AstraZeneca R&D Boston, Waltham, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Borodovsky","sequence":"additional","affiliation":[{"name":"Bioscience, AstraZeneca R&D Boston, Waltham, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eline","family":"Menu","sequence":"additional","affiliation":[{"name":"Department of Hematology and Immunology, Myeloma Center Brussels, Vrije Universiteit Brussel (VUB), Brussel, Massachusetts, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magne","family":"B\u00f8rset","sequence":"additional","affiliation":[{"name":"Center for Myeloma Research, Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU), Trondheim, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0860-8446","authenticated-orcid":false,"given":"Anne Marit","family":"Sponaas","sequence":"additional","affiliation":[{"name":"Center for Myeloma Research, Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU), Trondheim, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2020,5,14]]},"reference":[{"key":"2025100308454144000_8.1.e000610.1","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s00277-015-2522-9","article-title":"Changes in survival rate of multiple myeloma after the introduction of bortezomib: a single institutional experience over 20 years","volume":"95","author":"Fujisawa","year":"2016","journal-title":"Ann Hematol"},{"key":"2025100308454144000_8.1.e000610.2","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/248090"},{"key":"2025100308454144000_8.1.e000610.3","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0360-8"},{"key":"2025100308454144000_8.1.e000610.4","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2017.106"},{"key":"2025100308454144000_8.1.e000610.5","doi-asserted-by":"crossref","first-page":"694","DOI":"10.2119\/molmed.2016.00198","article-title":"Adenosine generated in the bone marrow niche through a CD38-mediated pathway correlates with progression of human myeloma","volume":"22","author":"Horenstein","year":"2016","journal-title":"Mol Med"},{"key":"2025100308454144000_8.1.e000610.6","doi-asserted-by":"publisher","DOI":"10.1038\/nrd2638"},{"key":"2025100308454144000_8.1.e000610.7","doi-asserted-by":"publisher","DOI":"10.1096\/fj.08-107458"},{"key":"2025100308454144000_8.1.e000610.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2003.11.003"},{"key":"2025100308454144000_8.1.e000610.9","doi-asserted-by":"publisher","DOI":"10.1038\/nri1685"},{"key":"2025100308454144000_8.1.e000610.10","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.0609388"},{"key":"2025100308454144000_8.1.e000610.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.scr.2011.04.001"},{"key":"2025100308454144000_8.1.e000610.12","doi-asserted-by":"publisher","DOI":"10.1016\/S0074-7696(08)62487-0"},{"key":"2025100308454144000_8.1.e000610.13","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20062512"},{"key":"2025100308454144000_8.1.e000610.14","doi-asserted-by":"publisher","DOI":"10.1007\/s11302-005-5302-5"},{"key":"2025100308454144000_8.1.e000610.15","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-12-064527"},{"key":"2025100308454144000_8.1.e000610.16","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-02-482406"},{"key":"2025100308454144000_8.1.e000610.17","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1458809","article-title":"Microvesicles released from multiple myeloma cells are equipped with ectoenzymes belonging to canonical and non-canonical adenosinergic pathways and produce adenosine from ATP and NAD","volume":"7","author":"Morandi","year":"2018","journal-title":"Oncoimmunology"},{"key":"2025100308454144000_8.1.e000610.18","doi-asserted-by":"publisher","DOI":"10.4161\/onci.26246"},{"key":"2025100308454144000_8.1.e000610.19","doi-asserted-by":"crossref","unstructured":"Emens L , Powderly Ii J , Fong L , et al . Abstract CT119: CPI-444, an oral adenosine A2A receptor (A2aR) antagonist, demonstrates clinical activity in patients with advanced solid tumors 2017;77. vol..","DOI":"10.1158\/1538-7445.AM2017-CT119"},{"key":"2025100308454144000_8.1.e000610.20","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1208875","article-title":"Targeting CD73 in the tumor microenvironment with MEDI9447","volume":"5","author":"Hay","year":"2016","journal-title":"Oncoimmunology"},{"key":"2025100308454144000_8.1.e000610.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2016.06.025"},{"key":"2025100308454144000_8.1.e000610.22","first-page":"129","article-title":"Anti-CD39 and anti-CD73 antibodies A1 and 7G2 improve targeted therapy in ovarian cancer by blocking adenosine-dependent immune evasion","volume":"6","author":"H\u00e4usler","year":"2014","journal-title":"Am J Transl Res"},{"key":"2025100308454144000_8.1.e000610.23","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1016\/j.celrep.2019.04.091","article-title":"Blocking antibodies targeting the CD39\/CD73 immunosuppressive pathway Unleash immune responses in combination cancer therapies","volume":"27","author":"Perrot","year":"2019","journal-title":"Cell Rep"},{"key":"2025100308454144000_8.1.e000610.24","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3109\/10428194.2014.907893","article-title":"Ectonucleoside triphosphate diphosphohydrolase-1 (E-NTPDase1\/CD39) as a new prognostic marker in chronic lymphocytic leukemia","volume":"56","author":"Abousamra","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"2025100308454144000_8.1.e000610.25","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v19.i12.1912"},{"key":"2025100308454144000_8.1.e000610.26","doi-asserted-by":"publisher","DOI":"10.1111\/j.0105-2896.2006.00362.x"},{"key":"2025100308454144000_8.1.e000610.27","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70442-5"},{"key":"2025100308454144000_8.1.e000610.28","doi-asserted-by":"crossref","first-page":"32024","DOI":"10.18632\/oncotarget.25882","article-title":"Pd1 is expressed on exhausted T cells as well as virus specific memory CD8+ T cells in the bone marrow of myeloma patients","volume":"9","author":"Sponaas","year":"2018","journal-title":"Oncotarget"},{"key":"2025100308454144000_8.1.e000610.29","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1997.409"},{"key":"2025100308454144000_8.1.e000610.30","doi-asserted-by":"publisher","DOI":"10.1067\/mob.2000.104832"},{"key":"2025100308454144000_8.1.e000610.31","first-page":"578","article-title":"Management of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM)","volume":"25","author":"Kyle","year":"2011","journal-title":"Oncology"},{"key":"2025100308454144000_8.1.e000610.32","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2014.11.002"},{"key":"2025100308454144000_8.1.e000610.33","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2008.08.005"},{"key":"2025100308454144000_8.1.e000610.34","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3955"},{"key":"2025100308454144000_8.1.e000610.35","doi-asserted-by":"crossref","unstructured":"Borodovsky A , Wang Y , Ye M , et al . Abstract 5580: Preclinical pharmacodynamics and antitumor activity of AZD4635, a novel adenosine 2A receptor inhibitor that reverses adenosine mediated T cell suppression. AACR. Cancer Research 2017;77. Abstract 5580.","DOI":"10.1158\/1538-7445.AM2017-5580"},{"key":"2025100308454144000_8.1.e000610.36","doi-asserted-by":"publisher","DOI":"10.1038\/sj.thj.6200052"},{"key":"2025100308454144000_8.1.e000610.37","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-04-568451"},{"key":"2025100308454144000_8.1.e000610.38","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-05072-0"},{"key":"2025100308454144000_8.1.e000610.39","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-018-0130-2"},{"key":"2025100308454144000_8.1.e000610.40","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.193"},{"key":"2025100308454144000_8.1.e000610.41","doi-asserted-by":"publisher","DOI":"10.1172\/JCI200215337"},{"key":"2025100308454144000_8.1.e000610.42","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2018.00196","article-title":"Cytokine-Induced killer cells express CD39, CD38, CD203a, CD73 ectoenzymes and P1 adenosinergic receptors","volume":"9","author":"Horenstein","year":"2018","journal-title":"Front Pharmacol"},{"key":"2025100308454144000_8.1.e000610.43","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2016.217"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2020-000610","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T15:45:49Z","timestamp":1759506349000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2020-000610"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,5,14]]},"published-print":{"date-parts":[[2020,5]]}},"alternative-id":["10.1136\/jitc-2020-000610"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2020-000610","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5]]}}}